

PRESS RELEASE

Gilbert Technologies Announces George Hersbach to serve as Executive Chairman and Transition Role of CEO to Current COO Maurits Huigen

EINDHOVEN, the Netherlands, January 31, 2022

Organizational update 2022

Gilbert Technologies B.V., an early stage Netherlands based MedTech company utilizing proprietary electro hydrodynamic atomization (EHDA) platform technology to create a next generation soft mist inhalation device for precise pulmonary drug administration, today announced the appointment of George Hersbach as Executive Chairman of the Board of Directors and the transition of current Chief Operating Officer, Maurits Huigen, to the role of Chief Executive Officer effective as of February 1, 2022.

“For the last five years, Maurits and I have worked closely on the development of our technology and to build Gilbert into the organization it is today. We have been making substantial progress on a variety of initiatives which includes the development of our first prototype, expanding our global intellectual property portfolio, and preparing for the next wave of growth that lies ahead,” said George Hersbach, Chairman & Chief Executive Officer of Gilbert Technologies. “Going forward, Maurits will assume the overall leadership of the company, while I will continue to chair and further expand the Board of Directors. In addition to that I will focus, in close collaboration with Maurits, on Gilbert’s financing, high-level strategy, intellectual property portfolio, and shareholder and investor relations.”

“It is a privilege to take on the role of CEO and lead the organization as we continue our progress towards our mission to redefine treatment for lung patients with difficult to treat conditions. The partnership George and I have built in guiding the company will continue,” said Maurits Huigen, Gilbert’s Chief Operating Officer. “I am very excited about 2022 and the opportunities we will have together with our partner Philips Engineering Solutions, to turn our proprietary soft mist technology into a first-of-a-kind medical inhaler device, which has the potential to improve effectiveness for patients and reduce medical costs. We are highly focused on getting to key inflection points on the development of our clinical device and our partnerships with pharmaceutical companies.”

Huigen ([Maurits Huigen | LinkedIn](#)) joined Gilbert in January 2017, serving as Chief Operating Officer. During his career in the pharmaceutical industry, Huigen has provided strategic- and executional leadership to companies as they scale, grow, and execute on the promise of their technologies. Before joining Gilbert, he held key leadership roles at several respiratory companies, including that of Managing Director of Chiesi Pharmaceuticals and as Market Group Manager at Teva Pharmaceuticals. Hersbach ([George J.M. Hersbach | LinkedIn](#)) co-founded Gilbert over 10 years ago with Delft University of Technology, the university from which he graduated. After his career in leading positions at bulk and specialty pharmaceutical companies, he founded his investment and corporate finance advisory firm Heartstream. He has an extensive and successful background in financing, including an initial public offering (in his former role as President & CEO of Pharming).

Both Hersbach and Huigen will continue to serve as members of the Company’s Board of Directors

Not for publication: For more information, please contact:

Gilbert Technologies B.V., High Tech Campus 27, P148, 5656 AE Eindhoven the Netherlands.
Maurits Huigen, Chief Executive Officer. E-mail: huigen@gilberttechnologies.eu. Tel: +31 62 790 9880.
Website: www.gilberttechnologies.eu.